Yuan Ji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3655894/publications.pdf

Version: 2024-02-01

134	4,301	30	58
papers	citations	h-index	g-index
143 all docs	143 docs citations	143 times ranked	6156 citing authors

#	Article	IF	CITATIONS
1	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	4.2	427
2	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	4.2	426
3	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 2010, 59, 953-962.	6.1	238
4	Aridla Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. Cancer Cell, 2017, 32, 574-589.e6.	7.7	172
5	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. Clinical Cancer Research, 2008, 14, 3850-3859.	3.2	143
6	A Pharmacogenomic Landscape in Human Liver Cancers. Cancer Cell, 2019, 36, 179-193.e11.	7.7	127
7	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer, 2018, 18, 1148.	1.1	113
8	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 547-559.	3.2	112
9	The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nature Medicine, 2014, 20, 596-598.	15.2	111
10	Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients—A single institution retrospective study of 292 lung adenocarcinoma. Journal of Surgical Oncology, 2013, 107, 474-480.	0.8	110
11	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 2021, 10, 320-329.	4.2	108
12	Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes. Cell Research, 2016, 26, 206-216.	5.7	105
13	Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer, 2014, 14, 38.	1.1	99
14	Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nature Cell Biology, 2019, 21, 1015-1026.	4.6	99
15	Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Medicine, 2018, 10, 42.	3.6	95
16	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nature Communications, 2021, 12, 4091.	5.8	90
17	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. Journal of Hepatology, 2022, 76, 608-618.	1.8	62
18	Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine, 2019, 41, 345-356.	2.7	59

#	Article	IF	CITATIONS
19	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	0.7	55
20	Efficacy and Safety of Endoscopic Submucosal Dissection forÂColorectal Carcinoids. Clinical Gastroenterology and Hepatology, 2016, 14, 575-581.	2.4	52
21	Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 465-475.	1.8	50
22	Wholeâ€tumor MRI histogram analyses of hepatocellular carcinoma: Correlations with Kiâ€67 labeling index. Journal of Magnetic Resonance Imaging, 2017, 46, 383-392.	1.9	49
23	UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability. Frontiers in Pharmacology, 2018, 9, 847.	1.6	48
24	Clinical features and surgical outcomes of pulmonary artery sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1109-1115.e1.	0.4	43
25	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Research, 2021, 9, 19.	2.8	43
26	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. BMC Cancer, 2017, 17, 58.	1.1	42
27	A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatology International, 2020, 14, 1034-1047.	1.9	42
28	NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. Journal of Hematology and Oncology, 2018, 11 , 28 .	6.9	41
29	Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nature Communications, 2022, 13, 1642.	5 . 8	40
30	Upstream open reading frame with NOTCH2NLC GGC expansion generates polyglycine aggregates and disrupts nucleocytoplasmic transport: implications for polyglycine diseases. Acta Neuropathologica, 2021, 142, 1003-1023.	3.9	34
31	Mitogenâ€activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelialâ€mesenchymal transition. Hepatology, 2015, 62, 1804-1816.	3.6	33
32	Evaluation of ADC measurements among solid pancreatic masses by respiratory-triggered diffusion-weighted MR imaging with inversion-recovery fat-suppression technique at 3.0T. Magnetic Resonance Imaging, 2013, 31, 524-528.	1.0	31
33	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death and Disease, 2018, 9, 1036.	2.7	31
34	Hepatocellular carcinoma repression by TNFαâ€mediated synergistic lethal effect of mitosis defectâ€induced senescence and cell death sensitization. Hepatology, 2016, 64, 1105-1120.	3 . 6	30
35	MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (â‰ g cm) with cirrhosis and chronic viral hepatitis: a comparative study. Clinical Imaging, 2014, 38, 265-272.	0.8	29
36	Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I. Scientific Reports, 2016, 6, 31460.	1.6	29

#	Article	IF	Citations
37	Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Human Pathology, 2015, 46, 850-857.	1.1	28
38	Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocrine Connections, 2018, 7, 169-178.	0.8	26
39	Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 204-204.	0.7	25
40	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti–Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transplantation, 2021, 27, 444-449.	1.3	24
41	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine, 2020, 62, 103107.	2.7	23
42	Microvascular invasion in hepatocellular carcinoma: is it predictable with a new, preoperative application of diffusion-weighted imaging?. Clinical Imaging, 2017, 41, 101-105.	0.8	22
43	Magnetic resonance texture analysis for the identification of cytokeratin 19-positive hepatocellular carcinoma. European Journal of Radiology, 2019, 117, 164-170.	1.2	22
44	<scp>DUSP</scp> 16 ablation arrests the cell cycle and induces cellular senescence. FEBS Journal, 2015, 282, 4580-4594.	2.2	20
45	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. Endocrine-Related Cancer, 2016, 23, L13-L16.	1.6	20
46	Solitary fibrous tumor of the liver. Hepatobiliary and Pancreatic Diseases International, 2006, 5, 151-3.	0.6	20
47	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer, 2018, 18, 702.	1.1	19
48	Grading Solid Pseudopapillary Tumors of the Pancreas: the Fudan Prognostic Index. Annals of Surgical Oncology, 2021, 28, 550-559.	0.7	17
49	Histogram Analysis of Diffusion Kurtosis Magnetic Resonance Imaging for Diagnosis of Hepatic Fibrosis. Korean Journal of Radiology, 2018, 19, 916.	1.5	16
50	Assessing liver fibrosis in chronic hepatitis B using MR extracellular volume measurements: Comparison with serum fibrosis indices. Magnetic Resonance Imaging, 2019, 59, 39-45.	1.0	16
51	MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas. European Journal of Radiology, 2019, 113, 7-14.	1.2	16
52	Nivolumab-associated DRESS in a genetic susceptible individual. , 2021, 9, e002879.		16
53	The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2001, 127, 559-564.	1.2	15
54	Combined treatment with TNF- $\hat{l}\pm/gef$ itinib alleviates the resistance to gefitinib in PC-9 cells. Anti-Cancer Drugs, 2009, 20, 832-837.	0.7	15

#	Article	IF	Citations
55	MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers. Abdominal Radiology, 2016, 41, 2102-2114.	1.0	15
56	Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocrine Connections, 2018, 7, 355-363.	0.8	15
57	Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. BMC Cancer, 2019, 19, 335.	1.1	15
58	Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma. Journal of Gastroenterology, 2020, 55, 1171-1182.	2.3	15
59	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial Journal of Clinical Oncology, 2021, 39, 4094-4094.	0.8	14
60	Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer. Diagnostic Pathology, 2017, 12, 41.	0.9	13
61	Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer. Scientific Reports, 2018, 8, 12868.	1.6	13
62	T 1 mapping on gadoxetic acid-enhanced MR imaging predicts recurrence of hepatocellular carcinoma after hepatectomy. European Journal of Radiology, 2018, 103, 25-31.	1.2	13
63	The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer, 2019, 22, 587-597.	2.7	13
64	Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study. American Journal of Surgery, 2020, 220, 945-951.	0.9	13
65	Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biology and Therapy, 2021, 22, 175-183.	1.5	13
66	A comparative study of MR extracellular volume fraction measurement and two-dimensional shear-wave elastography in assessment of liver fibrosis with chronic hepatitis B. Abdominal Radiology, 2019, 44, 1407-1414.	1.0	12
67	Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. Oncotarget, 2017, 8, 33185-33196.	0.8	12
68	A series of 64 cases of pancreatic cystic neoplasia from an institutional study of China. World Journal of Gastroenterology, 2006, 12, 7380.	1.4	12
69	Hepatic Loss of Borealin Impairs Postnatal Liver Development, Regeneration, and Hepatocarcinogenesis. Journal of Biological Chemistry, 2016, 291, 21137-21147.	1.6	11
70	Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection Journal of Clinical Oncology, 2020, 38, e16690-e16690.	0.8	11
71	Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. American Journal of Cancer Research, 2018, 8, 1040-1049.	1.4	11
72	MR imaging of hepatocellular adenomas on genotype-phenotype classification: A report from China. European Journal of Radiology, 2018, 100, 135-141.	1.2	10

#	Article	IF	Citations
73	Role of MR in the differentiation of IgG4-related from non-IgG4-related hepatic inflammatory pseudotumor. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 631-637.	0.6	9
74	ADC similarity predicts microvascular invasion of bifocal hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 2295-2302.	1.0	9
75	Microinvasion of liver metastases from colorectal cancer: predictive factors and application for determining clinical target volume. Radiation Oncology, 2015, 10, 125.	1.2	8
76	MR features of small hepatocellular carcinoma in normal, fibrotic, and cirrhotic livers: a comparative study. Abdominal Imaging, 2015, 40, 3062-3069.	2.0	8
77	<scp>HER</scp> 2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks. Histopathology, 2017, 71, 570-579.	1.6	8
78	The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review. Oncotarget, 2017, 8, 95023-95029.	0.8	8
79	Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center. Journal of Cancer, 2018, 9, 479-487.	1.2	8
80	Clinical features of 18 perivascular epithelioid cell tumor cases. Medicine (United States), 2020, 99, e21659.	0.4	8
81	Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy, 2020, 52, 727-735.	1.0	8
82	The role of GPR110 in lung cancer progression. Annals of Translational Medicine, 2020, 8, 745-745.	0.7	8
83	Staging Chronic Hepatitis B Related Liver Fibrosis with a Fractional Order Calculus Diffusion Model. Academic Radiology, 2022, 29, 951-963.	1.3	8
84	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget, 2016, 7, 76298-76307.	0.8	8
85	Serous cystic neoplasms of the pancreas: a clinicopathologic and immunohistochemical analysis [This article has been retracted]. Chinese Journal of Digestive Diseases, 2006, 7, 39-44.	1.1	7
86	Histogram analyses of diffusion kurtosis indices and apparent diffusion coefficient in assessing liver regeneration after ALPPS and a comparative study with portal vein ligation. Journal of Magnetic Resonance Imaging, 2018, 47, 729-736.	1.9	7
87	High Level of Legumain Was Correlated With Worse Prognosis and Peritoneal Metastasis in Gastric Cancer Patients. Frontiers in Oncology, 2020, 10, 966.	1.3	7
88	Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 13-20.	0.6	7
89	Abstract 486: A phase lb/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). Cancer Research, 2021, 81, 486-486.	0.4	7
90	The value of systemic inflammatory markers in identifying malignancy in mucinous pancreatic cystic neoplasms. Oncotarget, 2017, 8, 115561-115569.	0.8	7

#	Article	IF	Citations
91	Hepatocellular carcinoma with concomitant hepatic angiomyolipoma and cavernous hemangioma in one patient. World Journal of Gastroenterology, 2015, 21, 3414-3419.	1.4	7
92	Pancreatic primary lymphoma: a case report and review of the literature. Hepatobiliary and Pancreatic Diseases International, 2005, 4, 622-6.	0.6	7
93	Assessment of liver regeneration after associating liver partition and portal vein ligation for staged hepatectomy: a comparative study with portal vein ligation. Hpb, 2018, 20, 305-312.	0.1	6
94	Molecular profiling of the biphasic components of hepatic carcinosarcoma by the use of targeted nextâ€generation sequencing. Histopathology, 2019, 74, 944-958.	1.6	6
95	Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease. American Journal of Physiology - Renal Physiology, 2020, 319, G87-G96.	1.6	6
96	Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 1543.	1.3	6
97	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial Journal of Clinical Oncology, 2021, 39, 4099-4099.	0.8	6
98	Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms. Endocrine Connections, 2021, 10, 947-954.	0.8	6
99	Successful treatment of a case with pancreatic neuroendocrine carcinoma with focal hepatoid differentiation: a case report and literature review. International Journal of Clinical and Experimental Medicine, 2014, 7, 3588-94.	1.3	6
100	Clear cell sarcoma of the pancreas: a case report and review of literature. International Journal of Clinical and Experimental Pathology, 2015, 8, 2171-5.	0.5	6
101	Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features. Translational Oncology, 2019, 12, 646-655.	1.7	5
102	RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients. Open Medicine (Poland), 2020, 15, 167-174.	0.6	5
103	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma Journal of Clinical Oncology, 2021, 39, e16163-e16163.	0.8	5
104	Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment. Aging, 2019, 11, 10052-10060.	1.4	5
105	Liver computed tomographic perfusion for monitoring the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients. Journal of Cancer Research and Therapeutics, 2018, 14, 1556.	0.3	5
106	Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. American Journal of Translational Research (discontinued), 2018, 10, 3567-3578.	0.0	5
107	Retrospective study of hepatocellular adenomas based on the phenotypic classification system: A report from China. Histology and Histopathology, 2014, 29, 243-9.	0.5	5
108	Increased expression of \hat{I} ±Tubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Oncotarget, 2016, 7, 60657-60664.	0.8	4

#	Article	IF	Citations
109	Expert consensus on the scheme of pathological diagnosis of primary liver cancer. Chinese Clinical Oncology, 2012, 1, 12.	0.4	4
110	Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma. Annals of Translational Medicine, 2022, 10, 394-394.	0.7	4
111	Contrast-enhanced magnetic resonance imaging perfusion can predict microvascular invasion in patients with hepatocellular carcinoma (between 1 and 5Âcm). Abdominal Radiology, 2022, 47, 3264-3275.	1.0	4
112	Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma. Chinese Medical Journal, 2014, 127, 1211-7.	0.9	4
113	Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN. Frontiers in Oncology, 2022, 12, 802074.	1.3	4
114	The role of a multidisciplinary team in the management of portal hypertension. BMC Gastroenterology, 2020, 20, 83.	0.8	3
115	Complement activation in the arteries of patients with severe atherosclerosis. International Journal of Clinical and Experimental Pathology, $2018, 11, 1-9$.	0.5	3
116	Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World Journal of Clinical Cases, 2022, 10, 856-869.	0.3	3
117	Application of MSCT characteristic nomogram model in predicting invasion of pancreatic solid pseudopapillary neoplasms. European Journal of Radiology, 2022, 149, 110201.	1.2	3
118	Long-term prognosis of small gastric gastrointestinal stromal tumors with high histological grade: a longitudinal nested cohort study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4042-4049.	1.3	3
119	MR imaging of primary hepatic neuroendocrine neoplasm and metastatic hepatic neuroendocrine neoplasm: a comparative study. Radiologia Medica, 2015, 120, 1012-1020.	4.7	2
120	Colonic polypoid mucosa-associated lymphoid tissue lymphoma. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 101-102.	0.7	2
121	Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocrine Connections, 2018, 7, 1178-1185.	0.8	2
122	Nitric oxide synthase and vascular endothelial growth factor expression in hepatocellular carcinoma and the correlation with angiogenesis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2001, 13, 124-127.	0.7	1
123	Tolerance induction with donor hematopoietic stem cell infusion in kidney transplantation: a single-center experience in China with a 10-year follow-up. Annals of Translational Medicine, 2020, 8, 1378-1378.	0.7	1
124	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2021, 39, e16144-e16144.	0.8	1
125	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX) Journal of Clinical Oncology, 2016, 34, 4047-4047.	0.8	1
126	Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. Frontiers in Oncology, 2022, 12, 801924.	1.3	1

#	Article	IF	Citations
127	Heterogeneous Her2/Neu expression in gastric and gastroesophageal cancer—reply. Human Pathology, 2016, 48, 174-175.	1.1	О
128	Abstract 353: The translocations of FGFR2 and NTRK1 in intrahepatic cholangiocarcinoma and their discordance in status by FISH and IHC. , 2021, , .		0
129	Immunostaining by dual tumor tissue paraffin blocks increases the sensitivity of c-Met detection in gastric cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 5063-5071.	0.5	O
130	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. American Journal of Cancer Research, 2021, 11, 2044-2061.	1.4	0
131	Mucin profile of the pancreatic mucinous cystic neoplasms. Chinese Medical Journal, 2006, 119, 328-30.	0.9	O
132	Mucins in the diagnosis and differential diagnosis of pancreatic cystic neoplasms: report of 40 cases. Chinese Medical Journal, 2006, 119, 765-8.	0.9	0
133	Eosinophilic granulomatosis with polyangiitis is associated with hepatitis B virus infection. Clinical Rheumatology, 2022, , .	1.0	O
134	Genomic co-genotype classification and clinical prognosis in Ewing sarcoma Journal of Clinical Oncology, 2022, 40, e23532-e23532.	0.8	0